Hepatocyte-specific CLSTN3B ablation impairs lipid droplet maturation and alleviates diet-induced steatohepatitis in mice
Chuanhai ZhangiD, Dengbao YangiD, Hiroyuki SuzukiiD, Jingxuan CheniD, Jingjing WangiD, Mengchen YeiD, Jin ZhouiD, Qiyu Zeng, Meijuan BaiiD, Mei-Jung Lin, Jeon LeeiD, Hao ZhuiD, Yujin HoshidaiD, Xing ZengiD
Abstract
Excessive lipid accumulation in hepatocytes, a hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD), can lead to progressive liver damage. Understanding the molecular mechanisms governing lipid storage in hepatocytes is essential for identifying therapeutic targets to halt MASLD progression. Here, we show a pivotal role for the protein calsyntenin 3{beta} (CLSTN3B) in promoting lipid droplet (LD) maturation and lipid storage in hepatocytes. Previously characterized as an endoplasmic reticulum (ER)-LD contact protein that facilitates LD maturation in adipocytes, we now show that CLSTN3B expression is strongly induced in mouse hepatocytes by peroxisome proliferator-activated receptor gamma (PPAR{gamma}) in response to dietary caloric excess. Hepatocyte-specific deletion of CLSTN3B in mice significantly increases energy expenditure, reduces metabolic efficiency, and protects against diet-induced hepatic steatosis and fibrosis. Mechanistically, CLSTN3B deficiency causes reduced LD phospholipid coverage and increased lipase recruitment. This results in enhanced fatty acid oxidation driven by a futile cycle of lipolysis and re-esterification. Notably, human clinical data reveal a positive correlation between hepatic CLSTN3B expression and MASLD severity and progression, emphasizing its relevance to human disease. Together, our findings establish CLSTN3B as a key regulator of hepatocyte lipid storage and metabolic efficiency and highlight its potential as a therapeutic target in MASLD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Interorganelle competition for linoleic acid underlies steatotic liver pathology
Chuanhai Zhang, Dengbao Yang, … Xing Zeng·bioRxiv·Jan 11, 2026
- Inhibition of p107 alleviates liver steatosis by reducing de novo fatty acid synthesis.
Juan Cuñarro, Marta Varela Miguens, … Sulay A. Tovar·bioRxiv·Apr 16, 2026
- NR4A3 knockdown ameliorates metabolic dysfunction-associated steatotic liver disease through ATF3 transcriptional repression
Huiyan Liao, Linlin Zhou, Bo Qin·bioRxiv·Jun 30, 2026
- Lipid Droplet Targeting of ABHD5 and PNPLA3 I148M is required to promote liver steatosis
Grace Teskey, Nivedita Tiwari, … Emilio P. Mottillo·Journal of Biological ChemistryPeer-reviewed·Jan 13, 2025
- CLSTN3B enhances adipocyte lipid droplet structure and function via endoplasmic reticulum contact
- LncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ Signaling
Xianghong Xie, Mingyue Gao, … Xiaojun Liu·eLifePeer-reviewed·Oct 22, 2024